SBC Medical Group Holdings Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBC research report →
Range $9 – $15
Price Chart
About the company
SBC Medical Group Holdings Incorporated provides comprehensive operational support to aesthetic and cosmetic clinics across a global footprint, including Japan, Vietnam, the United States, and other international markets. The company delivers a diverse array of administrative and support functions, such as orchestrating marketing and advertising campaigns, offering extensive human resources solutions including talent acquisition and staff training, and streamlining appointment scheduling for franchisee clinics. Furthermore, SBC Medical Group facilitates real estate arrangements for both employee housing and clinic facility rentals, oversees the design and construction of new clinics, and manages the procurement of essential medical equipment and supplies.
- CEO
- Yoshiyuki Aikawa
- IPO
- 2022
- Employees
- 863
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on SBC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $531.72M
- P/E
- 12.24
- Fwd P/E
- 11.04
- PEG
- 0.64
- P/S
- 3.31
- P/B
- 2.07
- EV/EBITDA
- 5.64
- Div Yield
- 0.00%
- Gross Margin
- 72.02%
- Op Margin
- 39.89%
- Net Margin
- 27.26%
- ROE
- 19.38%
- ROIC
- 13.52%
Latest fiscal year · YoY change
- Revenue
- $173.61M-15.5%
- Gross Profit
- $127.28M-18.4%
- Op Income
- $67.49M
- Net Income
- $50.99M+9.4%
- EPS
- $0.50+4.2%
- OCF Growth
- +19.8%
- FCF Growth
- +29.8%
- 52W High
- $7.39
- 52W Low
- $2.78
- 50D MA
- $5.26
- 200D MA
- $3.99
- Beta
- 0.63
- RSI (14)
- 51
- Avg Volume
- 254.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SBC Medical said third-quarter growth re-accelerated, with revenue, profit, and margins all improving as same-clinic performance stayed solid and management outlined a longer-term push into longevity, AI, and international expansion.· November 13, 2026
- Revenue rose 35% year over year to $59 million; operating income increased 66%; adjusted EBITDA reached $28 million with a 47% margin.
- Basic EPS was $0.15, up 25% year over year; operating margin expanded from 37% to 45%.
- Same-clinic revenue for the first nine months rose 7% to $836 million, driven by more visits and higher spend per visit.
- The clinic network grew to 293 locations, up 36 year over year, while average spend per visit increased 4% to $290 over the trailing 12 months.
- Management said it plans to invest cash in M&A and de novo openings rather than buybacks, while continuing to improve liquidity and governance.
Third quarter revenue was $59 million, up 35% year over year. Income from operations was $26 million, up 66%, adjusted EBITDA was $28 million, up 66%, and adjusted EBITDA margin was 47%, up 9 points year over year. Basic EPS was $0.15, up 25%. For the first nine months, same-clinic revenue reached $836 million, up 7% year over year. Management did not provide formal next-quarter or full-year financial guidance, but said growth and margin expansion should continue over the mid to long term, with meaningful longevity revenue contribution expected from around 2028.
Yuya Yoshida framed the quarter as proof that SBC’s operating leverage is taking hold, emphasizing that profit growth is outpacing revenue growth. He said the company’s three-pronged strategy is now clear: sustain clinic productivity, build longevity capabilities, and use AI and U.S. expansion to create the next growth leg. His tone was confident and emphatic, repeatedly stressing that the business combines high growth, high margins, and net cash funding.
No separate CFO spoke on the call, so the financial commentary came from management. They highlighted the main drivers behind the $59 million in quarterly revenue: fee revisions announced in August, stronger rental revenue from newly opened clinics, and $5.6 million from the newly consolidated Waqoo segment. Management also pointed to a net cash balance sheet, said free cash flow funds expansion, and stated cash will be prioritized for M&A and de novo clinics rather than share repurchases at this time.
Analysts asked whether the 35% revenue growth and 47% adjusted EBITDA margin are sustainable, and management said growth is supported by multiple engines and should continue over the mid to long term, while AI should help profitability further. Questions on the U.S. strategy drew a response that OrangeTwist remains the main entry point, with at least one more clinic opening this quarter and plans for 8 to 10 additional clinics over the next three to four months, plus possible SBC-branded U.S. locations in the next 6 to 12 months. On capital allocation, management said liquidity is improving, cash will go to growth investments, and they are not considering additional buybacks now.
The quarter showed stronger-than-expected operating leverage, with profit growing faster than revenue and margins expanding meaningfully. Management also sees multiple future growth avenues: continued clinic expansion, non-aesthetic services, AI-driven efficiency gains, and a longevity platform that could start contributing meaningfully around 2028.
Management acknowledged intense competition in Japan and said many clinics have exited because they could not keep up with pricing pressure. Near-term revenue and margin contributions from longevity remain limited, and the company is still early in its U.S. strategy and in building the AI and diagnostic initiatives it is counting on for the next growth phase. Governance was also flagged by investors, with management admitting the board still lacks independent directors and saying the selection process is ongoing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 2.4%
- Shares Outstanding
- 102.85M
- Float Shares
- 2.47M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| American Century Investment Management Inc | 6.49M | ▲ 1.73M |
| Columbia Threadneedle Management Ltd | 1.00M | ▲ 1.00M |
| Trustco Bank | 37.37K | ▼ 1.36K |
Held by 67 ETFs
Biggest fund positions in SBC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Aikawa Yoshiyuki | sell | 465,000 |
| Apr 21, 26 | Aikawa Yoshiyuki | sell | 3,100,000 |
| Mar 6, 26 | Aikawa Yoshiyuki | sell | 4,422,900 |
| Mar 6, 26 | Aikawa Yoshiyuki | other | 44,229 |
| Mar 6, 26 | Aikawa Yoshiyuki | other | 44,229 |
| Apr 10, 25 | Yamazaki Miki | other | 0 |
| Sep 17, 24 | Aikawa Yoshiyuki | other | 0 |
| Sep 30, 24 | SAYAMA MIKE K | other | 15,000 |
| Sep 17, 24 | ZUU Co. Ltd. | other | 1,503,473 |
| Sep 19, 24 | ZUU Co. Ltd. | sell | 6,196 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SBC coverage
Recent articles, reports, and earnings notes.
No research on SBC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBC report →SBC Medical Group Holdings Incorporated (NASDAQ: SBC) INVESTIGATION ALERT: Portnoy Law Firm Announces Investigation into SBC Medical Group Holdings Incorporated Concerning Potential Securities Fraud
globenewswire.com · Nov 20
SBC Medical Group Reports Cybersecurity Incidents in Japan
gurufocus.com · Nov 19
SBC Medical Group Reports Cybersecurity Incidents in Japan
businesswire.com · Nov 18
Why SBC Medical Stock Skyrocketed on Friday
fool.com · Nov 13
SBC Medical Group Holdings Incorporated (SBC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
SBC Medical Group Q3 Earnings Call Highlights
marketbeat.com · Nov 13
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI
businesswire.com · Nov 13
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.